Navigation Links
Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
Date:9/20/2007

- Phase III data published in the American Journal of Nephrology -

DEERFIELD, Ill., Sept. 20 /PRNewswire-FirstCall/ -- Astellas Pharma US, Inc. today announced that its Phase III data on VAPRISOL was published in the September issue of the American Journal of Nephrology. In this study, VAPRISOL showed a significant increase in serum sodium concentrations in patients with hyponatremia -- a potentially life-threatening condition that occurs when the body's sodium level falls below normal.

"This study demonstrated that VAPRISOL 40 mg/day significantly increased serum [Na+] in patients with euvolemic or hypervolemic hyponatremia," said Joseph G. Verbalis, M.D., at the Georgetown University Hospital. "VAPRISOL will likely address an important clinical need for euvolemic or hypervolemic hyponatremia in hospitalized patients."

VAPRISOL is the first in a new class of arginine vasopressin (AVP) receptor antagonists. VAPRISOL blocks both V1a and V2 vasopressin receptors, resulting in increased urine output without increased sodium loss. This effect, known as "aquaresis," increases serum sodium levels and helps to restore salt and water balance in patients with hyponatremia due to increased body water (dilutional hyponatremia).

VAPRISOL is approved by the U.S. Food and Drug Administration as a treatment for euvolemic and hypervolemic hyponatremia in hospitalized patients. VAPRISOL is not indicated for the treatment of congestive heart failure. It should only be used for the treatment of hyponatremia in patients with underlying heart failure when the expected benefit of raising serum sodium outweighs the increased risk of adverse events. The approved doses for VAPRISOL include 20 mg/day and 40 mg/day. The 80 mg/day dose used in this study is not an approved dose.

In the double-blind, multicenter study, 84 patients with serum sodium levels of 115 to <130 mEq/L were randomized to receive placebo or a 20-mg intravenous bolus of conivaptan, followed by continuous infusion of conivaptan 40 mg/day (n=29) or 80 mg/day (n=26) for four days.

The primary endpoint of the study was the change from baseline in serum sodium levels over the entire course of treatment (expressed as the "area under the curve," or AUC). Secondary endpoints included: time to reach a >/= 4 mEq/L increase in serum sodium levels; total time during which patients had a >/= 4 mEq/L increase in serum sodium levels; change in serum sodium levels at day four; and number of patients who achieved a >/= 6 mEq/L increase in serum sodium levels or a normal serum sodium concentration (>/= 135 mEq/L) over the course of the study.

Both doses of VAPRISOL significantly improved serum sodium levels relative to placebo, with a mean change in AUC of 490.9 (mEq/L)hr in the VAPRISOL 40 mg/day group, 716.6 (mEq/L)hr in the VAPRISOL 80 mg/day group, and 12.9 (mEq/L)hr in the placebo group (p=0.001). On average, VAPRISOL 40 mg/day and 80 mg/day produced a >/= 4 mEq/L increase in serum sodium levels within 23.7 hours and 23.4 hours, respectively. Over the course of the study, patients receiving VAPRISOL 40 mg/day, 80 mg/day, or placebo experienced increases in serum sodium of >/= 4 mEq/L for 53.2 hrs, 72.7 hrs, and 14.2 hrs, respectively (p<.001). At study's end, the mean change in serum sodium concentration was 6.3 mEq/L in patients who received VAPRISOL 40 mg/day and 9.4 mEq/L in those who received VAPRISOL 80 mg/day, compared with 0.8 mEq/L in patients who were given placebo (p<.001). Sixty-nine percent of VAPRISOL 40 mg/day patients (p<.001) and 88.5 percent of VAPRISOL 80 mg/day patients (p<.001) achieved a >/= 6 mEq/L increase in serum sodium levels or a normal serum sodium concentration (>/= 135 mEq/L) over the treatment period, compared with 20.7 percent of patients receiving placebo.

Several treatment-emergent adverse events were more common in VAPRISOL patients than in placebo patients, including injection site phlebitis, hypotension and renal dysfunction.

Adverse events were mild or moderate in severity, and there were no differences in the rates of clinically meaningful serious adverse events across the study groups. However, discontinuations due to AEs were highest among patients given conivaptan 80 mg/day and were largely attributed to local infusion-site reactions.

Note: These study results were presented at the 2004 annual meeting of the Heart Failure Society of America in Toronto.

About Hyponatremia

Hyponatremia often results from elevated levels of the hormone arginine vasopressin (AVP), which regulates water and salt balance in the body. It is the most common electrolyte disorder in clinical medicine and one of the most difficult to treat.

Syndrome of inappropriate antidiuretic hormone (SIADH), advanced kidney failure, hypothyroidism, cancer and chronic high blood pressure are common causes of hyponatremia. Dilutional hyponatremia, which includes euvolemic and hypervolemic hyponatremia, is the most common form of the condition, and occurs when retained water dilutes serum sodium content. Patients with hyponatremia are classified as hypervolemic if swelling of body tissues (edema) is present or euvolemic if there is an increase in total body water content without edema.(1,2)

About VAPRISOL

Discovered and developed by Astellas Pharma Inc. headquartered in Tokyo, Japan, VAPRISOL is a novel drug that blocks the activity of AVP, resulting in increased urine output without loss of valuable electrolytes such as sodium and potassium. This effect, known as "aquaresis," helps to increase serum sodium levels in patients with hyponatremia, a condition of low serum sodium concentration, due to increased body water (dilutional hyponatremia). VAPRISOL is the first AVP receptor antagonist with a demonstrated safety profile and that effectively promotes aquaresis which helps to restore salt and water balance in patients with euvolemic and hypervolemic hyponatremia.

VAPRISOL is indicated for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients. VAPRISOL is not indicated for the treatment of congestive heart failure. It should only be used for the treatment of hyponatremia in patients with underlying heart failure when the expected benefit of raising serum sodium outweighs the increased risk of adverse events. VAPRISOL is contraindicated in patients with hypovolemic hyponatremia.

In addition, coadministration of VAPRISOL with potent CYP3A4 inhibitors, such as ketoconazole, itraconazole, clarithromycin, ritonavir, and indinavir, is contraindicated.

Serum sodium, volume, and neurological status must be monitored frequently because VAPRISOL potentially can cause overly rapid correction of sodium leading to serious sequelae. The use of VAPRISOL in patients with hepatic impairment (including ascites, cirrhosis, or portal hypertension) or renal impairment has not been systematically evaluated. Use caution when administering VAPRISOL to these patients.

The most common adverse reactions reported were infusion site reactions (incidence of 73% and 63% for 20 mg/day and 40 mg/day respectively) which were also the most common type of adverse reaction leading to discontinuation of VAPRISOL.

Discontinuations from treatment due to infusion site reactions were more common among VAPRISOL-treated patients (3%) than among placebo-treated patients (0%). Other common adverse reactions were headaches (8%, 10%), hypokalemia (22%, 10%), orthostatic hypotension (14%, 6%), and pyrexia (11%, 5%) for VAPRISOL 20mg/day and 40mg/day, respectively.

Complete prescribing information for VAPRISOL can be accessed at http://www.VAPRISOL.com.

About Astellas

Astellas Pharma US, Inc., located in Deerfield, Illinois, is a U.S. affiliate of Tokyo-based Astellas Pharma Inc., Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities. In the US, Astellas markets products in the areas of Immunology, Urology, Anti-Infectives, Cardiovascular and Dermatology. For more information about Astellas Pharma US, Inc., please visit our website at http://www.astellas.com/us.

References:

1. Goh KP. Management of hyponatremia. Am Fam Physician. 2004;

69:2387-2394.

2. Vachharajani TJ, Zaman F, Abreo KD. Hyponatremia in critically ill

patients. J Intensive Care Med. 2003;18:3-8.


'/>"/>
SOURCE Astellas Pharma US, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... 6, 2017  Diplomat Specialty Infusion Group, a brand of Diplomat ... its Iowa location. The ... now features an ISO 7 cleanroom—the standard needed to compound intravenous ... low level of pollutants. "Our ... and better serve our Iowa patients," said ...
(Date:6/2/2017)... , June 2, 2017  NxStage Medical, Inc. (Nasdaq: ... care, today announced new findings demonstrating positive biochemical outcomes ... System One™. The data will be presented at ... Madrid, Spain . ... Improve Home Dialysis Network in Europe ...
(Date:5/30/2017)... , May 30, 2017 Therapix Biosciences Ltd. ... specializing in the development of cannabinoid-based drugs, today ... company overview at three upcoming scientific and investor ... LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology:
(Date:6/20/2017)... , ... June 20, 2017 , ... ... contending that the introduction of school choice can promote economic development in economically ... school that has, according to the report, contributed to the economic development of ...
(Date:6/20/2017)... ... June 20, 2017 , ... AMC Health , the ... success in the clinical trials market. Similar to its approach in demonstrating positive outcomes ... clinical trials marketplace by proving the value of eVisits to support virtual studies. ...
(Date:6/20/2017)... ... ... Leading dental clinicians, Drs. Ashlyn Price, Autumn Mayers and Ron Adelman, now offer ... advanced digital images and modeling capabilities, the dentists identify all of the structures in ... for those who are missing teeth in Midlothian, VA. , In the ...
(Date:6/20/2017)... ... ... As a leading dental practice, Wall Centre Dental supports Stroke Awareness Month ... bleeding gums in Vancouver, BC, may be developing gingivitis, the first stage of ... and diabetes. Drs. Parviz Roshan, Siamak Tehrani and Milton Reskovich offer laser gum therapy ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... (AHN) Jefferson Hospital is providing physicians with advanced capabilities for diagnosing and treating ... than traditional MRIs, enabling doctors to get a more accurate look inside the ...
Breaking Medicine News(10 mins):